Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. Its lead product, DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, which is in Phase I/II clinical trials to treat inoperable solid tumors. The company was founded in 1996 and is headquartered in Bethesda, Maryland. more
Time Frame | NWBO | Sector | S&P500 |
---|---|---|---|
1-Week Return | -0.68% | -1.8% | -0.77% |
1-Month Return | -13.09% | -3.48% | 0.71% |
3-Month Return | -10.29% | -7.2% | 8.81% |
6-Month Return | -38.2% | -1.54% | 12.32% |
1-Year Return | -61.9% | 8.39% | 30.57% |
3-Year Return | -59.7% | 6.07% | 29.21% |
5-Year Return | 27.57% | 44.07% | 91.95% |
10-Year Return | -94.37% | 106.3% | 196.04% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 2.41M | 1.29M | 1.00M | 1.68M | 1.93M | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":53.57,"profit":true},{"date":"2021-12-31","value":41.7,"profit":true},{"date":"2022-12-31","value":69.83,"profit":true},{"date":"2023-12-31","value":80.17,"profit":true}] |
Cost of Revenue | 29.87M | 87.90M | 53.71M | - | - | [{"date":"2019-12-31","value":33.99,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":61.1,"profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Gross Profit | (27.46M) | (86.61M) | (52.70M) | - | - | [{"date":"2019-12-31","value":-2746300000,"profit":false},{"date":"2020-12-31","value":-8660500000,"profit":false},{"date":"2021-12-31","value":-5270200000,"profit":false},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Gross Margin | (1139.54%) | (6708.37%) | (5243.98%) | - | - | [{"date":"2019-12-31","value":-1139.54,"profit":false},{"date":"2020-12-31","value":-6708.37,"profit":false},{"date":"2021-12-31","value":-5243.98,"profit":false},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Operating Expenses | 29.87M | 87.90M | 53.71M | 68.86M | 57.44M | [{"date":"2019-12-31","value":33.99,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":61.1,"profit":true},{"date":"2022-12-31","value":78.35,"profit":true},{"date":"2023-12-31","value":65.35,"profit":true}] |
Operating Income | (27.46M) | (86.61M) | (52.70M) | (67.18M) | (55.51M) | [{"date":"2019-12-31","value":-2746300000,"profit":false},{"date":"2020-12-31","value":-8660500000,"profit":false},{"date":"2021-12-31","value":-5270200000,"profit":false},{"date":"2022-12-31","value":-6718100000,"profit":false},{"date":"2023-12-31","value":-5550800000,"profit":false}] |
Total Non-Operating Income/Expense | 7.17M | (443.22M) | 231.83M | (37.85M) | (7.09M) | [{"date":"2019-12-31","value":3.09,"profit":true},{"date":"2020-12-31","value":-191.18,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-16.33,"profit":false},{"date":"2023-12-31","value":-3.06,"profit":false}] |
Pre-Tax Income | (20.30M) | (529.82M) | 179.13M | (105.03M) | (62.60M) | [{"date":"2019-12-31","value":-11.33,"profit":false},{"date":"2020-12-31","value":-295.78,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-58.64,"profit":false},{"date":"2023-12-31","value":-34.95,"profit":false}] |
Income Taxes | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Income After Taxes | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Income From Continuous Operations | (20.30M) | (529.82M) | 179.13M | (105.03M) | (62.60M) | [{"date":"2019-12-31","value":-11.33,"profit":false},{"date":"2020-12-31","value":-295.78,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-58.64,"profit":false},{"date":"2023-12-31","value":-34.95,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (20.30M) | (529.82M) | 179.13M | (105.03M) | (62.60M) | [{"date":"2019-12-31","value":-11.33,"profit":false},{"date":"2020-12-31","value":-295.78,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-58.64,"profit":false},{"date":"2023-12-31","value":-34.95,"profit":false}] |
EPS (Diluted) | (0.05) | (0.76) | 0.19 | (0.10) | (0.06) | [{"date":"2019-12-31","value":-27.03,"profit":false},{"date":"2020-12-31","value":-404.45,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-51.14,"profit":false},{"date":"2023-12-31","value":-30.21,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
NWBO | |
---|---|
Current Ratio | 0.09 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
NWBO | |
---|---|
ROA (LTM) | -137.16% |
ROE (LTM) | 0.00% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
NWBO | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 3.71 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | -2.71 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
NWBO | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 222.27 |
P/B | 0.00 |
Price/FCF | NM |
EV/R | 274.04 |
EV/Ebitda | NM |
PEG | NM |
Northwest Biotherapeutics Inc (NWBO) share price today is $0.28
Yes, Indians can buy shares of Northwest Biotherapeutics Inc (NWBO) on Vested. To buy Northwest Biotherapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in NWBO stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Northwest Biotherapeutics Inc (NWBO) via the Vested app. You can start investing in Northwest Biotherapeutics Inc (NWBO) with a minimum investment of $1.
You can invest in shares of Northwest Biotherapeutics Inc (NWBO) via Vested in three simple steps:
The 52-week high price of Northwest Biotherapeutics Inc (NWBO) is $0.86. The 52-week low price of Northwest Biotherapeutics Inc (NWBO) is $0.24.
The price-to-earnings (P/E) ratio of Northwest Biotherapeutics Inc (NWBO) is
The price-to-book (P/B) ratio of Northwest Biotherapeutics Inc (NWBO) is 0.00
The dividend yield of Northwest Biotherapeutics Inc (NWBO) is 0.00%
The market capitalization of Northwest Biotherapeutics Inc (NWBO) is $376.26M
The stock symbol (or ticker) of Northwest Biotherapeutics Inc is NWBO